OncologyMerck
Merck Receives FDA Approval for Keytruda as First-Line Treatment for Bladder Cancer
BMI
Biotechnology Media Insights
Editorial Team · May 12, 2025
Merck announces FDA approval of Keytruda (pembrolizumab) plus enfortumab vedotin for previously untreated locally advanced or metastatic urothelial carcinoma.
Merck today announced that the FDA has approved Keytruda (pembrolizumab) in combination with enfortumab vedotin for the first-line treatment of adults with locally advanced or metastatic urothelial carcinoma. The combination reduced the risk of death by 53% compared to chemotherapy.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.